Company Verona Pharma plc London S.E.

Equities

VRP

GB00BYW2KH80

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

Delayed London S.E. Other stock markets 12:35:15 2020-10-29 pm EDT			5-day change	1st Jan Change
55 ^GBX	+5.77%		+4.76%	-11.29%

Jul. 16	European Equities Traded in the US as American Depositary Receipts Lower in Tuesday Trading	MT
Jul. 15	European Equities Traded in the US as American Depositary Receipts Start Week Lower in Monday Trading	MT

Verona Pharma Plc is a United Kingdom-based biopharmaceutical company. The Company is focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. Its product candidate, ensifentrine, is an investigational, inhaled, small molecule and dual inhibitor of the enzymeâs phosphodiesterase 3 and 4 (PDE3 and PDE4) combining bronchodilator and non-steroidal anti-inflammatory activities in one compound. It is engaged in developing inhaled ensifentrine for the treatment of chronic obstructive pulmonary disease (COPD). The Company's two additional formulations of ensifentrine are in Phase II development for the treatment of COPD: dry powder inhaler (DPI) and pressurized metered-dose inhaler (pMDI). The Company's wholly owned subsidiary is Verona Pharma, Inc.

Managers	Title	Age	Since
David Zaccardelli CEO	Chief Executive Officer	59	20-01-31
Mark Hahn DFI	Director of Finance/CFO	61	20-02-29
Kavita Aggarwal CTO	Chief Tech/Sci/R&D Officer	-	22-12-31
Tara Rheault CTO	Chief Tech/Sci/R&D Officer	49	18-12-31
Kathleen Rickard CTO	Chief Tech/Sci/R&D Officer	65	19-01-31
Victoria Stewart IRC	Investor Relations Contact	-	19-01-31
Christopher Martin PRN	Corporate Officer/Principal	-	20-05-31
Ostra Jewell HRO	Human Resources Officer	-	22-08-31
Caroline Diaz LAW	General Counsel	-	21-09-30
Matthew Casbon SAM	Sales & Marketing	-	22-08-23

Members of the board	Title	Age	Since
Mahendra Shah BRD	Director/Board Member	79	16-06-16
Vikas Sinha BRD	Director/Board Member	60	16-09-11
David Ebsworth CHM	Chairman	69	14-11-30
Ken Cunningham Cunningham BRD	Director/Board Member	71	15-09-09
Martin Edwards BRD	Director/Board Member	68	19-03-31
Sven Anders Ullman BRD	Director/Board Member	68	15-09-09
David Zaccardelli CEO	Chief Executive Officer	59	20-01-31
Christina Ackermann BRD	Director/Board Member	59	23-08-31
Lisa Deschamps BRD	Director/Board Member	52	21-02-28
James Brady BRD	Director/Board Member	61	22-03-13

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	608,138,246	458,671,402 ( 75.42 %)	0	75.42 %

Name	Equities	%	Valuation
RA Capital Management LP 7.792 %	6,317,990	7.792 %	91 M p
NEA Management Co. LLC 6.301 %	5,108,563	6.301 %	74 M p
Deep Track Capital LP 5.077 %	4,116,549	5.077 %	60 M p
Wellington Trust Co., NA 4.822 %	3,909,466	4.822 %	57 M p
Perceptive Advisors LLC 4.639 %	3,761,576	4.639 %	54 M p
Vivo Capital LLC 4.453 %	3,610,177	4.453 %	52 M p
OrbiMed Advisors Private Equity 4.191 %	3,398,067	4.191 %	49 M p
Deep Track Capital LP 3.931 %	3,187,415	3.931 %	46 M p
Frazier Life Sciences Management LP 3.718 %	3,014,349	3.718 %	44 M p
Abingworth LLP 3.031 %	2,457,500	3.031 %	36 M p

Name	Equities	%	Valuation
Access Industries, Inc. (New York) 6.860 %	32,946,296	6.860 %	60 M p
David Zaccardelli 3.301 %	15,854,048	3.301 %	29 M p
Mark Hahn 3.111 %	14,943,032	3.111 %	27 M p
David Ebsworth 1.174 %	5,637,123	1.174 %	10 M p
Sven Anders Ullman 0.5578 %	2,678,848	0.5578 %	5 M p
Kathleen Rickard 0.5458 %	2,621,552	0.5458 %	5 M p
Claire Poll 0.5422 %	2,604,311	0.5422 %	5 M p
Martin Edwards 0.1920 %	922,248	0.1920 %	2 M p
Vikas Sinha 0.1240 %	595,520	0.1240 %	1 M p
Mahendra Shah 0.1217 %	584,640	0.1217 %	1 M p

Verona Pharma Plc

3 More London Riverside

SE1 2RE, London

+44 20 3283 4200

http://www.veronapharma.com

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

22.26 USD

Average target price

36.17 USD

Spread / Average Target

+62.47%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	+20.17%	126B
REGENERON PHARMACEUTICALS, INC.	+24.67%	118B
ARGENX SE	+23.38%	27.87B
BIONTECH SE	-17.74%	20.95B
GENMAB A/S	-16.24%	16.92B
BEIGENE, LTD.	-15.21%	16.18B
NEUROCRINE BIOSCIENCES, INC.	+11.91%	14.84B
WUXI APPTEC CO., LTD.	-47.10%	14.79B
SAREPTA THERAPEUTICS, INC.	+54.50%	14.08B

Bio Therapeutic Drugs